PT1140139E - Utilizacao de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral - Google Patents

Utilizacao de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral

Info

Publication number
PT1140139E
PT1140139E PT99966958T PT99966958T PT1140139E PT 1140139 E PT1140139 E PT 1140139E PT 99966958 T PT99966958 T PT 99966958T PT 99966958 T PT99966958 T PT 99966958T PT 1140139 E PT1140139 E PT 1140139E
Authority
PT
Portugal
Prior art keywords
erythropoietin
treatment
cerebral
ischaemia
cerebral ischemia
Prior art date
Application number
PT99966958T
Other languages
English (en)
Portuguese (pt)
Inventor
Hannelore Ehrenreich
Christophe Gleiter
Original Assignee
Hannelore Ehrenreich
Christoph Gleiter
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7891015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1140139(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hannelore Ehrenreich, Christoph Gleiter filed Critical Hannelore Ehrenreich
Publication of PT1140139E publication Critical patent/PT1140139E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
PT99966958T 1998-12-14 1999-12-13 Utilizacao de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral PT1140139E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19857609A DE19857609A1 (de) 1998-12-14 1998-12-14 Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen

Publications (1)

Publication Number Publication Date
PT1140139E true PT1140139E (pt) 2004-04-30

Family

ID=7891015

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99966958T PT1140139E (pt) 1998-12-14 1999-12-13 Utilizacao de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral

Country Status (26)

Country Link
US (1) US7514072B1 (enExample)
EP (1) EP1140139B2 (enExample)
JP (2) JP4750947B2 (enExample)
KR (1) KR100774827B1 (enExample)
CN (1) CN1187085C (enExample)
AT (1) ATE253932T1 (enExample)
AU (1) AU766216C (enExample)
BG (1) BG65417B1 (enExample)
BR (1) BR9916197A (enExample)
CA (1) CA2353553C (enExample)
DE (2) DE19857609A1 (enExample)
DK (1) DK1140139T4 (enExample)
ES (1) ES2211218T5 (enExample)
HK (1) HK1042655B (enExample)
HU (1) HUP0104709A3 (enExample)
ID (1) ID29107A (enExample)
IL (2) IL143579A0 (enExample)
MX (1) MXPA01005971A (enExample)
NO (1) NO330079B1 (enExample)
NZ (1) NZ541591A (enExample)
PL (1) PL202483B1 (enExample)
PT (1) PT1140139E (enExample)
RO (1) RO121409B1 (enExample)
RU (1) RU2242991C2 (enExample)
WO (1) WO2000035475A2 (enExample)
ZA (1) ZA200104626B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US7345019B1 (en) 1999-04-13 2008-03-18 The Kenneth S. Warren Institute, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US7309687B1 (en) 1999-04-13 2007-12-18 The Kenneth S. Warren Institute, Inc. Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
KR101012932B1 (ko) * 1999-04-13 2011-02-08 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
US7078376B1 (en) 2000-08-11 2006-07-18 Baxter Healthcare S.A. Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
US6531121B2 (en) 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en) 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
WO2003018782A2 (en) 2001-08-30 2003-03-06 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use theeof
ATE541921T1 (de) 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
DE10219545A1 (de) * 2002-04-26 2003-11-06 Lang Florian Regulation der Apoptose
EP1535065A4 (en) * 2002-06-11 2007-07-11 Burnham Inst NEUROPROTECTOR SYNERGY OF ERYTHROPOIETIN AND INSULIN-LIKE GROWTH FACTOR
DE10234192B4 (de) 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
MXPA05010345A (es) * 2003-03-27 2006-03-08 Johnson & Johnson Uso de la eritropoyetina en la recuperacion del accidente cerebrovascular.
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
ZA200603396B (en) 2003-09-29 2007-11-28 Warren Pharmaceuticals Inc Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
AU2004285448C1 (en) 2003-10-23 2021-08-19 Otsuka Pharmaceutical Co., Ltd. Controlled release sterile injectable aripiprazole formulation and method
WO2005077404A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US9988427B2 (en) 2005-05-13 2018-06-05 Charite Universitaetsmedizen-Berlin Erythropoietin variants
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
EP1933814A2 (en) * 2005-09-15 2008-06-25 Elan Pharma International Limited Nanoparticulate aripiprazole formulations
EP1928488A4 (en) 2005-09-27 2009-07-22 Stem Cell Therapeutics Corp REGULATION OF OLIGODENDROCYTE PRECURSOR CELL PROLIFERATION WITH PROLACTIN
CA2643502A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Dosing regimes for lh or hcg and epo for treatment of neurological disorders
NZ573792A (en) * 2006-06-07 2011-09-30 Univ Tokushima Treatment of ischemic disease using erythropoietin mobilised mononuclear cells
JP4879349B2 (ja) * 2007-07-31 2012-02-22 大塚製薬株式会社 アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法
RU2446834C2 (ru) * 2010-06-15 2012-04-10 Елена Александровна Лебедева Способ лечения пострадавших с сочетанной черепно-мозговой травмой
US9956265B2 (en) 2011-04-26 2018-05-01 Ajou University Industry-Academic Cooperation Foundation Composition for aiding surgical procedures for treating ischemic vascular diseases
RU2495688C1 (ru) * 2012-03-28 2013-10-20 Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" Способ лечения ишемии головного мозга в эксперименте
US9610444B2 (en) 2013-03-15 2017-04-04 Pacesetter, Inc. Erythropoeitin production by electrical stimulation
KR20190052855A (ko) 2017-11-09 2019-05-17 대한제당 주식회사 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
JPS6197229A (ja) 1984-10-18 1986-05-15 Chugai Pharmaceut Co Ltd 安定なエリトロポエチン製剤
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US5013718A (en) * 1986-11-21 1991-05-07 Amgen, Inc. Method for treating iron overload using EPO
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
EP0452484B2 (en) 1989-11-06 2004-07-28 Cell Genesys, Inc. Production of proteins using homologous recombination
ATE156189T1 (de) 1989-12-22 1997-08-15 Applied Research Systems Modifikation der endogenen genexpression mit hilfe eines regulatorischen elements mittels homologe rekombination
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
PT101031B (pt) 1991-11-05 2002-07-31 Transkaryotic Therapies Inc Processo para o fornecimento de proteinas por terapia genetica
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
JP3537151B2 (ja) 1991-12-26 2004-06-14 中外製薬株式会社 脳機能障害による疾患の予防・治療薬
RU2068268C1 (ru) * 1992-03-19 1996-10-27 Учебно-научный центр Медицинского центра при Правительстве РФ Способ профилактики церебро-васкулярных заболеваний
US5614184A (en) 1992-07-28 1997-03-25 New England Deaconess Hospital Recombinant human erythropoietin mutants and therapeutic methods employing them
US5661125A (en) 1992-08-06 1997-08-26 Amgen, Inc. Stable and preserved erythropoietin compositions
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
EP0744953A4 (en) 1993-04-29 1998-05-06 Abbott Lab METHODS AND COMPOSITIONS OF ERYTHROPO ETINE ANALOGS
ZA946122B (en) 1993-08-17 1995-03-20 Amgen Inc Erythropoietin analogs
SE520730C2 (sv) 1995-01-20 2003-08-19 Eskil Elmer Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
US6121246A (en) * 1995-10-20 2000-09-19 St. Elizabeth's Medical Center Of Boston, Inc. Method for treating ischemic tissue
US6165783A (en) 1997-10-24 2000-12-26 Neuro Spheres Holdings Ltd. Erythropoietin-mediated neurogenesis
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
KR101012932B1 (ko) 1999-04-13 2011-02-08 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 말초 투여된 에리트로포에틴에 의한 흥분조직의 기능조절법
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs

Also Published As

Publication number Publication date
DK1140139T3 (da) 2004-03-15
HK1042655B (zh) 2005-09-23
MXPA01005971A (es) 2002-03-27
ZA200104626B (en) 2002-09-06
CN1335776A (zh) 2002-02-13
JP2011079860A (ja) 2011-04-21
WO2000035475A2 (de) 2000-06-22
RU2242991C2 (ru) 2004-12-27
AU766216C (en) 2004-11-11
BG105575A (en) 2002-01-31
WO2000035475A3 (de) 2000-10-19
DK1140139T4 (da) 2009-06-08
NO330079B1 (no) 2011-02-14
DE19857609A1 (de) 2000-06-15
EP1140139B1 (de) 2003-11-12
EP1140139A2 (de) 2001-10-10
PL349335A1 (en) 2002-07-15
CN1187085C (zh) 2005-02-02
AU766216B2 (en) 2003-10-09
KR100774827B1 (ko) 2007-11-07
HUP0104709A2 (hu) 2002-04-29
ATE253932T1 (de) 2003-11-15
BG65417B1 (bg) 2008-07-31
DE59907752D1 (de) 2003-12-18
EP1140139B2 (de) 2009-03-18
NZ541591A (en) 2007-08-31
NO20012896D0 (no) 2001-06-12
RO121409B1 (ro) 2007-05-30
JP4750947B2 (ja) 2011-08-17
ES2211218T5 (es) 2009-06-03
US7514072B1 (en) 2009-04-07
EP1140139B9 (de) 2004-03-31
HK1042655A1 (en) 2002-08-23
PL202483B1 (pl) 2009-06-30
BR9916197A (pt) 2001-09-04
KR20010082346A (ko) 2001-08-29
IL143579A (en) 2007-10-31
NO20012896L (no) 2001-08-14
JP2002532432A (ja) 2002-10-02
IL143579A0 (en) 2002-04-21
ES2211218T3 (es) 2004-07-01
CA2353553A1 (en) 2000-06-22
AU2283100A (en) 2000-07-03
CA2353553C (en) 2011-05-17
HUP0104709A3 (en) 2002-05-28
ID29107A (id) 2001-07-26

Similar Documents

Publication Publication Date Title
PT1140139E (pt) Utilizacao de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral
EP4442241A3 (en) Retinol replacement in skin treatment
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
ES2157005T3 (es) Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina.
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
ATE141045T1 (de) Schlankmachende zusammensetzung
WO2006098603A3 (en) Composition comprising isoorientin for suppressing histamine
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
ATE277608T1 (de) 2-arachidonylglycerol, ein hemmer des tumor nekrose faktors -alfa und neuroprotektor des gehirns bei geschlossenen kopfverletzungen
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
EA200400436A1 (ru) Медикаменты для профилактики и лечения бромидроза
BR0213479A (pt) Utilização do irbesartan para a preparação de medicamentos úteis para a prevenção ou o tratamento da hipertensão pulmonar
EP1297849A4 (en) CURATIVE AGENT FOR OPTICAL AND SIMILAR NERVE DISEASES
DE60306503D1 (de) Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion
BR0312778A (pt) Composição farmacêutica para prevenção ou tratamento de arteriosclerose ou doenças derivadas de arteriosclerose, e, usos de um antagonista de receptor de adp e de um inibidor de acat
ES2105643T3 (es) Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer.
HUP0204180A2 (hu) Külsőleges készítmény és alkalmazása allergiás dermatitisz kezelésére
PT1235573E (pt) Associacao de riluzole e de gabapentina e sua utilizacao como medicamento no tratamento das doencas motoneuronais
IS2392B (is) Sítalópram til að meðhöndla hækkaðan blóðþrýsting
IL197035A0 (en) Pharmaceutical formula for treating skin disease
BR0312283A (pt) Combinação compreendendo um agente de alquilação e um agente redutor da atividade de vegf
IT1310326B1 (it) Pomata per la cura delle lesioni cutanee particolarmente delle ustioni
PL1700597T3 (pl) Kompozycja farmaceutyczna do podawania na skórę, zawierająca łącznie ubidekarenon, despantenol oraz chlorheksydynę lub jej farmakologicznie dopuszczalną sól